medigraphic.com

2021, Number 1

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2021; 22 (1)

Cavernous hemangioma

Chércoles CLE, Sánchez GD, Díaz SF

Language: Spanish
References: 13
Page: 1-10
PDF size: 490.02 Kb.


ABSTRACT

Cavernous hemangioma is a benign neoplasm of blood vessels. This work aimed at presenting the case of a giant cavernous hemangioma treated with propranolol. The diagnosis was made by physical examination, duplex Doppler sonography, and complementary tests of interest. For deciding the therapeutic approach, the patient was assessed by several specialists from different medical fields, such as oncology, dermatology, orthopedics, pediatrics, and angiology. Once the treatment was established, a follow-up was carried out for four weeks and then monthly. The outcome, after twenty-two months, was the hemangioma disappearance. Propranolol in giant cavernous hemangioma should be the treatment of early choice for a satisfactory evolution and to avoid complications.


REFERENCES

  1. Hernández-Zepeda C, García-Romero MT. Hemangiomas infantiles. Acta Pediatr Mex. 2017 [acceso 04/04/2020];38(3):202-7. Disponible en: http://www.ojs.actapediatrica.org.mx/index.php/APM/article/viewFile/1391/958

  2. Baselga Torresa E, Bernabéu Wittelb J, van Esso Arbolavec DL, Febrer Boschd MI, Carrasco Sanze Á, de Lucas Lagunaf R, et al. Consenso español sobre el hemangioma infantil An Pediatr (Barc). 2016 [acceso 04/04/2020];85(5):256-65. Disponible en: http://www.analesdepediatria.org/es-consenso-español-sobre-el-hemangioma

  3. Metry DW. Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications. En: Levy ML. Pediatric Dermatology. 2020 [acceso 04/04/2020]. Disponible en: https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology

  4. Ma X, Zhao T, Ouyang T, Xin S, Ma Y, Chang M. Int. Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells. J Clin Exp Pathol. 2014 [access 04/04/2020];15(7):3809-17. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25120757

  5. Zhang L, Mai HM, Zheng J, Zheng JW, Wang YA, Qin ZP, et al. Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. J Clin Exp Pathol. 2013 Dec 15 [acceso 07/05/2020];7(1):48-55. Disponible en: http://www.europepmc.org/abstract/MED/23217879

  6. Labastida-Gómez de la Torre O, Moreno-Vázquez K. Tratamientos actuales de hemangiomas infantiles. Dermatol Rev Mex. 2016 [acceso 07/05/2020];60(4):319-25. Disponible en: https://www.medigraphic.com/pdfs/derrevmex/rmd- 2016/rmd164f

  7. Prabha N, Chhabra N, Arora R. Beta-blockers in dermatology. Indian. J Dermatol Venereol Leprol. 2017 May-Jun [acceso 04/04/2020];83(3):399. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28366914

  8. Kim KH, Choi TH, Choi Y, Park YW, Hong KY, Kim DY, et al. Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial. JAMA Dermatol. 2017 [acceso 04/04/2020];153:529-36. Disponible en: https://pubmed.ncbi.nlm.nih.gov/2416056

  9. Chang L, Ye X, Qiu Y, Ma G, Jin Y, Chen H, et al. Is propranolol safe and effective for outpatient use for infantile hemangioma? A prospective study of 679 cases from one center in China. Ann Plast Surg. 2016 [acceso 04/04/2020];76:559-63. Disponible en: https://www.nature.com/articles/pr2017220

  10. Léauté-Labrèze C. Hemangioma infantil y Propranolol. SEMINAR. 2017;390:85-9. DOI: http://www.dx.doi.org/10.1016/S0140-6736(16)00645-0

  11. Lindsey EH. Infantile hemangioma: AAP Releases guideline for management. Am Fam Physician. 2019 [acceso 04/04/2020];100(3):186-7. Disponible en: https://www.aafp.org/afp/2019/0801/p186.html

  12. Smithson SL, Rademaker M, Adams S, Bade S, Bekhor P, Davidson S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol. Australas J Dermatol. 2017 May [acceso 04/04/2020];58(2):155-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28251611

  13. Chércoles Cazate LE, Díaz Socarrás FJ. Algunas especificidades sobre los hemangiomas externos en niños. MEDISAN. 2018 [acceso 08/05/2020];22(3). Disponible en: http://www.medisan.sld.cu/index.php/san/author/submission/1881




2020     |     www.medigraphic.com